Neurofilament Light Chain to Predict Progression of Degenerative Brain Disorder

Neurology Advisor | June 6, 2017

Levels of neurofilament light chain (NfL) in cerebrospinal fluid (CSF) and plasma can help predict the rate of disease progression in patients with progressive supranuclear palsy (PSP).

Results of the prospective study were presented at the 2017 International Congress of Parkinson's Disease and Movement Disorders.

Previous studies have demonstrated the utility of CSF NfL levels for the differentiation of atypical parkinsonian disorders from Parkinson's disease2; however there is limited evidence supporting the ability of serial measurements of CSF and plasma NfL to track and predict disease progression.3-5With markers of clinical disease progression integral to the measurement of efficacy of disease-modifying therapies, a team of investigators led by Professor Huw Morris and Edwin Jabbari, MBBS, of University College London in the United Kingdom, sought to evaluate whether CSF and plasma NfL could predict the speed of PSP disease progression.

Read the rest of the article and find the references at neurologyadvisor.com